10 results about "Kininogen" patented technology

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The invention provides a preparation method of an aprotinin affinity chromatographic column. Specifically, the aprotinin is used as a raw material and is coupled with CNBr activated agarose gel Focurose 4FF to prepare the aprotinin affinity chromatographic column. The coupling reaction in the preparation method is simple and easy to control, the reaction condition is mild, the operation is convenient, the repeatability is high, and industrial amplification is easy. The affinity column prepared by the invention can completely remove human urinary kallidinogenase in urokinase, and can be repeatedly used for multiple times.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.

The application provides a kind of nanobody specifically binding to pancreatic kallikrein, wherein the nucleotide sequence of the nanobody is as shown in any one of SEQ ID No.1, 3, 5.The application also provides corresponding applications.The application successfully screens and identifies anti-pancreatic kallikrein nanobody with good expression activity, uses pichia pastoris system to express and produce, can greatly reduce production cost, and is more conducive to the industrialization of the antibody;It also successfully constructs the purification filler using anti-pancreatic kallikrein nanobody as accessory, and lays a good foundation for subsequent purification of pancreatic kallikrein.

The application provides a kind of nanobody specifically binding to pancreatic kallikrein, wherein the nucleotide sequence of the nanobody is as shown in any one of SEQ ID No.1, 3, 5.The application also provides corresponding applications.The application successfully screens and identifies anti-pancreatic kallikrein nanobody with good expression activity, uses pichia pastoris system to express and produce, can greatly reduce production cost, and is more conducive to the industrialization of the antibody;It also successfully constructs the purification filler using anti-pancreatic kallikrein nanobody as accessory, and lays a good foundation for subsequent purification of pancreatic kallikrein.

Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.

The application provides a kind of nanobody specifically binding to pancreatic kallikrein, wherein the nucleotide sequence of the nanobody is as shown in any one of SEQ ID No.1, 3, 5.The application also provides corresponding applications.The application successfully screens and identifies anti-pancreatic kallikrein nanobody with good expression activity, uses pichia pastoris system to express and produce, can greatly reduce production cost, and is more conducive to the industrialization of the antibody;It also successfully constructs the purification filler using anti-pancreatic kallikrein nanobody as accessory, and lays a good foundation for subsequent purification of pancreatic kallikrein.

An siRNA which inhibits kininogen (KNG) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I, nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotide differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotide differences. The siRNA, the pharmaceutical composition thereof and the siRNA conjugate can effectively treat and / or prevent septicemia.

This invention discloses a detection kit for residual urokinase protein, its preparation method, and its application. The detection kit includes a capture antibody and a detection antibody. The capture antibody includes a polyclonal antibody against residual urokinase protein, and the detection antibody includes a biotin-labeled polyclonal antibody against residual urokinase protein. The polyclonal antibody against residual urokinase protein is obtained by repeatedly immunizing animals with residual urokinase protein as an immunogen. The residual urokinase protein is obtained by further purifying crude human urinary kininogenase by adsorption and removal of urokinase using an affinity column with an anti-urokinase monoclonal antibody. This invention fills the gap in the detection of residual drug proteins in urinary sources. It has high specificity, an antibody coverage rate of over 70%, and a method quantification limit of approximately 4 ng / ml. It has a low detection limit and high sensitivity for residual urokinase protein, requires no expensive instruments, and is easy to operate.